海利生物
(603718)
| 流通市值：48.11亿 | | | 总市值：49.15亿 |
| 流通股本：6.44亿 | | | 总股本：6.58亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 174,428,026.55 | 107,598,422.2 | 70,304,397.74 | 240,722,981.59 |
| 营业收入 | 174,428,026.55 | 107,598,422.2 | 70,304,397.74 | 240,722,981.59 |
| 二、营业总成本 | 210,114,237.84 | 132,630,744.76 | 79,483,781.34 | 247,650,829.86 |
| 营业成本 | 88,818,920.59 | 56,188,837.28 | 39,553,800.94 | 117,004,710.95 |
| 税金及附加 | 2,273,480.53 | 1,444,689.52 | 790,907.96 | 3,146,351.4 |
| 销售费用 | 35,785,269.02 | 21,956,251.58 | 11,428,246.56 | 40,831,894.06 |
| 管理费用 | 62,962,578.79 | 39,343,258.41 | 21,100,810.08 | 58,942,170.49 |
| 研发费用 | 16,830,160.27 | 11,393,089.37 | 5,495,990.24 | 24,971,937.68 |
| 财务费用 | 3,443,828.64 | 2,304,618.6 | 1,114,025.56 | 2,753,765.28 |
| 其中:利息费用 | 3,821,868.26 | 2,610,502.28 | 1,343,984.59 | 5,389,081.95 |
| 其中:利息收入 | 412,700.61 | 324,451.23 | 236,226.73 | 2,677,282.65 |
| 加:公允价值变动收益 | -848,057.4 | -523,717.79 | 1,443,832.22 | -16,517,666.02 |
| 加:投资收益 | 7,675,102.94 | 4,344,665.84 | 857,854.31 | 73,140,499.3 |
| 资产处置收益 | - | - | - | 606,062.98 |
| 资产减值损失(新) | - | - | - | -3,297,108.44 |
| 信用减值损失(新) | -2,169,615.69 | -137,174.26 | 706,834.99 | -1,030,209.43 |
| 其他收益 | 3,615,546.28 | 3,111,209.32 | 657,675.24 | 9,196,896.81 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -27,413,235.16 | -18,237,339.45 | -5,513,186.84 | 55,170,626.93 |
| 加:营业外收入 | 34,780,874.15 | 34,780,799.38 | 2,894.51 | 948,454.3 |
| 减:营业外支出 | 90,369.35 | 61,156.94 | 15,700.01 | 96,601.4 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 7,277,269.64 | 16,482,302.99 | -5,525,992.34 | 56,022,479.83 |
| 减:所得税费用 | -8,131,720.34 | 6,106,193.56 | -1,164,889.12 | 6,008,711.66 |
| 六、净利润 | 15,408,989.98 | 10,376,109.43 | -4,361,103.22 | 50,013,768.17 |
| 持续经营净利润 | 15,408,989.98 | 10,376,109.43 | -4,361,103.22 | 50,013,768.17 |
| 归属于母公司股东的净利润 | 20,173,396.25 | 15,124,957.25 | -3,719,366.81 | 62,870,202.71 |
| 少数股东损益 | -4,764,406.27 | -4,748,847.82 | -641,736.41 | -12,856,434.54 |
| (一)基本每股收益 | 0.03 | 0.02 | -0.01 | 0.1 |
| (二)稀释每股收益 | 0.03 | 0.02 | -0.01 | 0.1 |
| 八、其他综合收益 | 1,568,638.59 | -8,903,502.5 | -8,270,656.09 | 13,001,673.01 |
| 归属于母公司股东的其他综合收益 | 1,568,638.59 | -8,903,502.5 | -8,270,656.09 | 13,001,673.01 |
| 九、综合收益总额 | 16,977,628.57 | 1,472,606.93 | -12,631,759.31 | 63,015,441.18 |
| 归属于母公司股东的综合收益总额 | 21,742,034.84 | 6,221,454.75 | -11,990,022.9 | 75,871,875.72 |
| 归属于少数股东的综合收益总额 | -4,764,406.27 | -4,748,847.82 | -641,736.42 | -12,856,434.54 |
| 公告日期 | 2024-10-31 | 2024-08-31 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |